Pedro Pablo Medina Vico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6144716/publications.pdf

Version: 2024-02-01

52 papers 3,619 citations

279701 23 h-index 254106 43 g-index

55 all docs 55 docs citations

55 times ranked 6205 citing authors

#	Article	IF	CITATIONS
1	OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010, 467, 86-90.	13.7	877
2	Regression of murine lung tumors by the let-7 microRNA. Oncogene, 2010, 29, 1580-1587.	2.6	465
3	MicroRNAs and cancer: An overview. Cell Cycle, 2008, 7, 2485-2492.	1.3	325
4	FGF Regulates TGF-Î ² Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression. Cell Reports, 2012, 2, 1684-1696.	2.9	265
5	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Human Mutation, 2008, 29, 617-622.	1.1	226
6	DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy. Journal of Clinical Oncology, 2006, 24, 4333-4339.	0.8	132
7	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	2.6	130
8	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004, 23, 4037-4040.	2.6	111
9	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes and Cancer, 2004, 41, 170-177.	1.5	103
10	The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancerâ€. Human Molecular Genetics, 2009, 18, 1343-1352.	1.4	99
11	Expression signatures in lung cancer reveal a profile for <i>EGFR</i> â€mutant tumours and identify selective <i>PIK3CA</i> overexpression by gene amplification. Journal of Pathology, 2008, 214, 347-356.	2.1	92
12	Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics, 2008, 3, 64-68.	1.3	92
13	Maslinic acid, a triterpenic anti-tumoural agent, interferes with cytoskeleton protein expression in HT29 human colon-cancer cells. Journal of Proteomics, 2013, 83, 15-25.	1.2	64
14	Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene, 2004, 23, 5084-5091.	2.6	61
15	Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Human Molecular Genetics, 2005, 14, 973-982.	1.4	55
16	Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives. Current Organic Chemistry, 2015, 19, 919-947.	0.9	53
17	Maslinic Acid, a Natural Triterpene, Induces a Death Receptor-Mediated Apoptotic Mechanism in Caco-2 p53-Deficient Colon Adenocarcinoma Cells. PLoS ONE, 2016, 11, e0146178.	1.1	43
18	Antitumour activity on extrinsic apoptotic targets of the triterpenoid maslinic acid in p53-deficient Caco-2 adenocarcinoma cells. Biochimie, 2013, 95, 2157-2167.	1.3	37

#	Article	IF	CITATIONS
19	Gene amplification of the transcription factor DP1 and <i>CTNND1</i> in human lung cancer. Journal of Pathology, 2010, 222, 89-98.	2.1	33
20	Maslinic Acid, a Triterpene from Olive, Affects the Antioxidant and Mitochondrial Status of B16F10 Melanoma Cells Grown under Stressful Conditions. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-11.	0.5	33
21	Inhibiting microRNA function in vivo. Nature Methods, 2009, 6, 37-38.	9.0	31
22	Target molecules in 3T3-L1 adipocytes differentiation are regulated by maslinic acid, a natural triterpene from Olea europaea. Phytomedicine, 2016, 23, 1301-1311.	2.3	27
23	Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics, 2015, 24, 1400-1409.	1.4	26
24	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia, 2020, 34, 2722-2735.	3.3	24
25	The oleanolic acid derivative, 3-O-succinyl-28-O-benzyl oleanolate, induces apoptosis in B16–F10 melanoma cells via the mitochondrial apoptotic pathway. RSC Advances, 2016, 6, 93590-93601.	1.7	23
26	SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature Communications, 2021, 12, 4319.	5.8	22
27	Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2019, 9, 93.	2.8	20
28	SWI/SNF proteins as targets in cancer therapy. Journal of Hematology and Oncology, 2014, 7, 81.	6.9	17
29	Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer. Oncogene, 2020, 39, 5479-5493.	2.6	13
30	The value of lncRNAFENDRRandFOXF1as a prognostic factor for survival of lung adenocarcinoma. Oncotarget, 2020, 11, 1172-1185.	0.8	12
31	Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency. PLoS ONE, 2021, 16, e0252848.	1.1	12
32	BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. Clinical and Translational Oncology, 2017, 19, 1010-1017.	1,2	11
33	The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung. Upsala Journal of Medical Sciences, 2020, 125, 19-29.	0.4	11
34	Microarray Profiling of Mononuclear Peripheral Blood Cells Identifies Novel Candidate Genes Related to Chemoradiation Response in Rectal Cancer. PLoS ONE, 2013, 8, e74034.	1.1	10
35	Preoperative chemoradiotherapy for rectal cancer: the sensitizer role of the association between miR-375 and c-Myc. Oncotarget, 2017, 8, 82294-82302.	0.8	8
36	LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma. Cancers, 2020, 12, 2080.	1.7	7

#	Article	IF	CITATIONS
37	LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancers, 2020, 12, 3803.	1.7	7
38	Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes. Blood, 2022, 139, 2406-2410.	0.6	7
39	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. Cancers, 2020, 12, 3712.	1.7	6
40	Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma. Clinical Epigenetics, 2022, 14, 42.	1.8	5
41	PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer. Cellular Oncology (Dordrecht), 2022, 45, 323-332.	2.1	4
42	Long Noncoding RNAs as Cancer Biomarkers. , 2018, , 95-114.		3
43	Wiping DNA Methylation: Wip1 Regulates Genomic Fluidity on Cancer. Cancer Cell, 2013, 24, 405-407.	7.7	2
44	The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma. Human Molecular Genetics, 2021, 30, 2263-2271.	1.4	2
45	SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a,) Tj ETQq1	1 0,78431 0.1	4 rgBT /Overl
46	P2.02-010 Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer Journal of Thoracic Oncology, 2017, 12, S2101-S2102.	0.5	0
47	MA17.06 Plakophilin 1 Enhances MYC Expression, Promoting Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S319.	0.5	0
48	P1.03-20 Exploring Driver Mutations in Non-Coding RNAs in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, S425.	0.5	0
49	EP1.14-36 Suicide Gene Therapy Directed by MicroRNA Activity. Journal of Thoracic Oncology, 2019, 14, S1046.	0.5	0
50	Abstract 5052: Pro-oncogenic role of desmosomal plaque-related proteins in non-small cell lung cancer (NSCLC). , 2016, , .		0
51	Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs. , 2016, , .		0
52	Opportunities of miRNAs in cancer therapeutics. , 2022, , 153-164.		0